companydata.dkY-mAbs Therapeutics A/S: Financial statements 2018
CVR: 37053678
Y-mAbs Therapeutics A/S (CVR 37053678) has filed annual accounts for 2018. In 2018, the company reported a gross profit of DKK 28,598,680 and a net result of DKK -4,193,681 compared with DKK -2,177,894 the year before. That is an increase of 116.8% compared with the year before. Equity amounted to DKK 1,614,476. The solvency ratio was 9.4%. The company had 19 employees in the financial year.
- Gross Profit
- 28,598,680 kr.
- Profit/Loss
- -4,193,681 kr.
- Equity
- 1,614,476 kr.
- Total Assets
- 17,236,728 kr.
- Employees
- 19
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2018 | - | 28.6 mio. | -4.2 mio. | 1.6 mio. | 19 |
| 2017 | - | 13.2 mio. | -2.2 mio. | 808 t. | - |
Keep an eye on Y-mAbs Therapeutics A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2018
As of December 18, 2018, Gérard Ber has joined the board of directors of Y-mAbs Therapeutics A/S.
As of December 18, 2018, Michael Joachim Buschle has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2017. Gross profit came to DKK 13,194,221, and the net result was DKK -2,177,894.
As of January 18, 2018, Ashutosh Tyagi has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 18, 2018, David Neil Gill has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 18, 2018, Michael Joachim Buschle has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 18, 2018, Jim Irvin Healy has joined the board of directors of Y-mAbs Therapeutics A/S.
About Y-mAbs Therapeutics A/S
Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 24 employees. In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity amounted to DKK -163,651,844.